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Abstract Before the advent of diagnostic imaging, nuclear medicine was a treat-
ment modality. The first therapeutic application of radioisotopes was almost con-
temporaneous with the discovery of radioactivity. P-32 became one of the first
effective therapies for a range of malignant blood disorders; I-131 was established
as the benchmark for the treatment of metastatic thyroid cancer; Sr-89 was
recognised to provide palliative benefit in advanced prostate cancer. The develop-
ment of tomographic imaging with SPECT and PET, further enhanced by hybrid
CT or MRI devices, has recently focussed the speciality of nuclear medicine on the
diagnostic use of isotopes. Against this trend there has been renewed awareness on
the ability of radiotracers to identify potential therapeutic targets and to use this
information to select patients for and to monitor the efficacy of targeted therapies
using radioisotopes. This process has been termed “theranostics”. A significant
factor in the rebirth of therapeutic nuclear medicine has been the development of
peptides labelled with Ga-68 and Lu-177. Ga-68 DOTA-octreotate PET/CT and
Lu-177 DOTA-octreotate peptide receptor radionuclide therapy (PRRT) provides
the modern prototype of the theranostic paradigm. Experience with PRRT has,
however, emphasised the need for a more rigorous scientific approach to radionu-
clide therapy. The future holds promise of wide range of therapeutic options based
on diagnostic/therapeutic pairs including I-124/I-131 and Cu-64/Cu-67. Quantita-
tive SPECT/CT and PET/CT will be key platform technologies for planning and
monitoring such therapy and will realise the true promise of molecular imaging in
characterising rather than just finding disease.
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21.1 Introduction
Many current practitioners working in nuclear medicine are unaware of its rich
history as a therapeutic modality. For interested readers, a delightful series of
anecdotes and historical vignettes are contained in Marshall Brucer’s “A Chronol-
ogy of Nuclear Medicine” (Publisher: Robert R Butaine (September 1990) ISBN-
10: 096256740X, ISBN-13: 978–0962567407). To summarise this fascinating tale
of discovery, serendipity and human sacrifice are beyond the scope of this paper but
I will try to cover its key events in order to provide a background to current
advances in nuclear medicine practice that I believe will be fundamental to its
future evolution.
21.2 Radioisotopes Become Therapeutic Tools
Shortly after the discovery of radioactivity in naturally occurring elements by Henri
Becquerel in 1896 and the subsequent isolation of radium byMarie and Pierre Curie
in 1898, Pierre Curie became aware of the potential of radioactive elements to
damage cells, when he himself sustained a very slow healing radiation ulcer on his
chest after carrying a sample of radium to a lecture at the Sorbonne in Paris. Louis
Pasteur opined that chance favours the prepared mind. In this case, this simulta-
neously unfortunate but fortuitous event led Pierre Curie to ponder whether radium
might have potential therapeutic application in the treatment of malignant skin
lesions. In a seminal example of translational research, he discussed this with a
medical colleague, Henri-Alexandre Danlos, who successfully treated patients with
aggressive squamous cell and basal cell cancers. This quickly led to the dissemi-
nation of radium throughout the world for treatment, first of skin cancers and, later,
of all manner of malignancies. Intra-tumoural administration of radium was a
forerunner of modern brachytherapy. However, it soon became clear that despite,
at times, dramatic therapeutic effects, this treatment, particularly when adminis-
tered systemically, could have significant side effects, including death but, partic-
ularly, haematological disorders and, in the case of radium, osteosarcoma. Marie
Curie herself died of aplastic anaemia. Although this has been attributed to her
exposure to radioisotopes, she also would have received substantial radiation while
using unshielded X-rays while operating a field ambulance service in World War 1.
The development of the cyclotron by Ernest O. Lawrence provided a range of
new isotopes [1]. One of these, P-32, was found to suppress blood counts, and again
in a serendipitous manner, Lawrence’s brother was a haematologist and decided to
try this agent for the treatment of a patient. This patient was, in fact, a medical
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student, with chronic myeloid leukaemia. The dramatic benefit from this treatment
led to its use in a range of other blood malignancies. P-32 remains a useful
treatment for myeloproliferative syndromes, especially in the elderly who tolerate
chemotherapy poorly. In studying calcium metabolism using Sr-89, a Belgian by
the name of Charles Pecher believed he had discovered a cure for metastatic
prostate cancer following dramatic and complete pain relief in a patient suffering
from advanced stages of this disease. Although this discovery was lost for a period
of time due to a combination of the untimely death by suicide of Pecher and
suppression of information about the American nuclear weapons program, it was
“rediscovered” in the 1970s and was the first of a range of bone-seeking radiophar-
maceuticals that came into widespread use in the 1980s and 1990s [2]. In studying
thyroid function using I-130 in the 1930s, the development of hypothyroidism was
recognised and leveraged for the treatment of thyrotoxicosis. Subsequently, Glenn
Seaborg and John Livingood made I-131 and Sam Seidlin applied it to the treatment
of metastatic thyroid cancer in the 1940s [3]. It has since become an integral part of
the management of thyroid cancer. The ability to iodinate biologically relevant
molecules was translated into other therapies including I-131 metaiodobenzyl-
guanidine. I was privileged to be trained in therapeutic nuclear medicine at the
University of Michigan by the some of the pioneers of this therapy, James Sisson
and Brahm Shapiro [4]. This treatment remains an important therapeutic option for
the treatment of metastatic phaeochromocytoma and paraganglioma and also in
refractory neuroblastoma [5]. While these therapeutic techniques have continued to
be used by nuclear medicine physicians, with the exception of I-131 therapy of
thyroid cancer, they are often seen as the treatment of last resort after surgery,
chemotherapy, targeted agents and radiotherapy have failed.
21.3 The Rise and Rise of Imaging
In evaluating the uptake and retention of I-131 in thyroid cancer metastases, Sam
Seidlin used a Geiger-Muller counter since nuclear imaging hadn’t been conceived.
It wasn’t until the advent of the rectilinear scanner, conceived by Benedict Cassen,
that it became possible to image the internal distribution of radiopharmaceuticals.
In the first of many seminal contributions to the field of nuclear medicine, David
Kuhl combined photographic film to the rectilinear scanner to create the
photoscanner [6]. He subsequently developed the principles of tomographic imag-
ing while being a resident in the Radiology Department of the University of
Pennsylvania [7]. Using an Am-245 source, he created the first transmission scan,
a forerunner of X-ray computed tomography [8], and also performed emission
tomography, the forerunner of single-photon emission computed tomography
(SPECT) [9]. Gordon Brownell developed coincidence detection to acquire
multiplanar images from positron-emitting radionuclides, and Michael Phelps and
Ed Hoffman adopted this approach and combined it with the tomographic method
developed by Kuhl to create positron emission tomography (PET). The first human
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scanner was released in 1976 [10]. The real revolution in PET came with the
development of the glucose analogue F-18 fluorodeoxyglucose (FDG) [11]. It
was both fortunate and tragic that FDG was one of the first PET tracers to become
available. Its excellent performance for evaluating diseases of the heart [12] and
brain [13] and more recently cancer has stifled the clinical application of other PET
tracers. Even its lack of specificity in whole-body imaging mode has found appli-
cation for the imaging of infection and inflammation.
Throughout the world FDG PET/CT has become the dominant molecular imag-
ing technique for evaluating cancer with demonstrated effectiveness in diagnosis,
staging, therapeutic response assessment and restaging. Further, it provides infor-
mation of about the biological aggressiveness of tumours. With the addition of
anatomical landmarks from CT, some see FDG as the ideal “contrast agent” for
cancer detection and has encouraged many to consider nuclear medicine as a
diagnostic imaging technique that should be integrated into radiology. This view
has been strengthened by the development of hybrid PET-MRI scanners, which
have a particular strength in localisation of disease sites.
The wider availability of PET/CT scanners has, however, made positron-
emitting radiopharmaceuticals that were developed and used in the era of rectilinear
scanners but which fell out of favour with the introduction of the gamma camera,
attractive again. F-18 sodium fluoride (NaF) was formerly a widely used agent for
bone scanning but was replaced by Tc-99 m bisphosphonates in routine nuclear
medicine practice as the gamma camera replaced rectilinear scanners. NaF PET/CT
is, however, clearly superior to Tc-99 m MDP SPECT/CT in terms of spatial and
contrast resolution, enhancing both sensitivity and specificity [14]. Gallium-68 is
another example of an old radionuclide being seen in a new light and will be
addressed later.
The major focus of much PET radiopharmaceutical development has, however,
been on compounds labelled with fluorine-18. This is a radionuclide that is easily
produced in small cyclotrons in abundant quantities after a relatively short period of
target irradiation. Its physical half-life is attractive both for distribution and imag-
ing. In my own department we chose to establish fluorinated PET tracers in
addressing areas in which FDG has demonstrable weaknesses and the alternative
SPECT agents are also suboptimal. As a result, the amino acid analogue, F-18
fluoro-ethyl-tyrosine (FET), which has low uptake in normal brain tissue but
enhanced transport into brain tumours, has replaced both FDG PET and Tl-201
SPECT brain tumour imaging in our facility [15], as it has in many other centres
[16]. Similarly, the proliferation tracer, F-18 fluorothymidine (FLT) provides a
conceptually more robust evaluation of the status of bone marrow function than
does a range of techniques previously used to assess this using a gamma camera.
Whereas we previously utilised either radiolabelled white blood cells or Tc-99 m
antimony colloid scanning, we now exclusively use FLT to assess bone marrow
reserves [17] or to assess unexplained cytopaenias. Preliminary data suggests a
potential role of this agent for assessing leukaemias [18]. Similarly, agents such as
F-18 fluoro-methyl-choline (FCH) have also found a clinical role in the evaluation
of cancers that tend to have low uptake of the conventional oncological PET tracer,
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FDG [19]. Prostate cancer and lobular breast cancer are notable examples
[20]. Table 21.1 provides a list of fluorinated agents routinely used in my depart-
ment for oncological indications. We have a range of other F-18-labelled agents
that are still being evaluated in clinical trials. These include an agent with high
specificity for melanin, an attractive target for imaging malignant melanoma.
Despite the attraction of F-18, there remained many aspects of oncological
imaging practice that were still best served by single-photon-emitting radionu-
clides. This situation has more recently been addressed by development of gal-
lium-68-based tracers. The germanium-gallium-68 generator has reintroduced a
radionuclide that was first described more than 50 years ago. Providing an alterna-
tive to the technetium-99 m generator, Ga-68 provides the option of centres without
immediate access to a cyclotron, or even those with access to cyclotron products, to
a potentially wide array of radiotracers that can replace existing nuclear medicine
techniques.
The most established of these tracers are the somatostatin analogues, which have
significantly impacted the management of patients with a range of neuroendocrine
tumour (NET) [21]. Where available, these Ga-68 agents have largely replaced the
conventional nuclear medicine imaging technique of In-111 DTPA-octreotide
scintigraphy due to a combination of significantly enhanced diagnostic accuracy,
greater patient convenience and more favourable radiation dosimetry. However,
there is a range of other agents that could rapidly enter into routine nuclear
medicine practice. These include agents for renal scanning [22] and ventilation-
perfusion imaging [23]. Table 21.2 provides a list of Ga-68-labelled agents that are
used clinically in my department.
There has also been a move to replace I-131, which has unfavourable imaging
and radiation dose characteristics with I-123 for SPECT/CT diagnostic imaging.
We clearly preferred this agent to I-131, but when comparing it to FDG, the
technical differences between the scans often limited comparison of tracer avidity,
particularly for small lesions. Accordingly, we have moved to using I-124, partic-
ularly in patients likely to come to I-131-based therapy. The treatment of metastatic
thyroid cancer, phaeochromocytoma/paraganglioma, neuroblastoma and
Table 21.1 Fluorinated tracers used clinically at the Peter MacCallum Cancer Centre





18F-fluoro-thymidine FLT Cell proliferation Marrow status
Tumour proliferation




Prostate cancer, lobular breast
cancer





FAZA Hypoxia Assessment for hypoxia
cytotoxins
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lymphoma with iodinated products has opened the way for the “theranostic”
application of I-124-labelled tracers. Table 21.3 provides a list of I-124 compounds
used clinically in my department.
In addition to these tracers, we are involved in developing further agents for
clinical PET scanning or validating agents that have been developed elsewhere.
These include agents labelled with Cu-64 and Zr-89. These agents will play, we
believe, an important role in further advancing the safety and efficacy of radionu-
clide therapy as well as putting it on a solid scientific footing. Table 21.4 provides a
list of agents that are being evaluated prior to moving into routine clinical use.
This catalogue of tracers is not limited by opportunities for further relevant
clinical applications but rather by the challenges posed by producing such a large
array of tracers in an academic department, particularly in the context of increas-
ingly stringent requirements for product to comply with good manufacturing
practice (GMP). We have partly overcome these issues by partnering with a
commercial supplier of PET tracers who have helped to transition tracers from
the research domain into routine clinical practice by producing and distributing
GMP-certified agents more widely. By achieving economies of scale not feasible in
a hospital-based radiopharmacy, tracers like FLT, FET and NaF are now readily
available to other PET facilities in our region. As experience with these tracers has
grown, the role of PET has become ever more enthusiastically embraced by medical
Table 21.2 Gallium-68 tracers used clinically at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
68Ga-DOTA-octreotate GaTate SSTR NET
Phaeo/PGL
68Ga-DOTA-exendin-4 Ga-GLP-1 GLP-1 receptor Insulinoma/MTC
68Ga-nano-aerosol Galligas Ventilation VQ scanning
68Ga-macro-aggregated
albumin
Ga-MAA Lung perfusion VQ scanning
68Ga-EDTA Ga-EDTA Renal filtration Renal scanning




68Ga-nano-colloid Ga-colloid Phagocytosis SLN imaging
68Ga-tropolone Ga-RBC Blood products Blood pool
imaging
SSTR somatostatin receptor, NET neuroendocrine tumour, Phaeo/PGL phaeochromocytoma/
paraganglioma, SNL sentinel lymph node, RBC red blood cell
Table 21.3 Iodine-124 tracers used clinically at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
124I-iodide I-124 NaI symporter Thyroid cancer




and radiation oncologists as well as by surgeons. There are, in many countries,
impediments to dissemination of these techniques as a result of health technology
assessment regimes that require a significantly higher level of evidence than existed
for older technologies prior to allowing their use and, particularly, reimbursing their
cost. Notwithstanding these limitations, it seems inevitable that hybrid PET devices
will become the preferred diagnostic imaging technique in cancer at least [24].
21.4 The Slow Rebirth of Radionuclide Therapy
Many hoped that small-molecule kinase inhibitors that target specific mutations in
cancer cells would be the final solution in cancer therapy. The dramatic metabolic
responses seen in gastrointestinal stromal tumours (GISTs) provided great excite-
ment, as this was a disease previously without effective therapies. The use of BRAF
inhibitors to combat the most common mutation in malignant melanoma was
similarly ground-breaking and again accompanied by marked and early metabolic
response in FDG PET [25]. However, it has become very clear that resistance to
such agents develops almost universally, sometimes after only a brief response.
This resistance arises due to genomic heterogeneity and evolution of tumours under
the selective pressure of signal transduction blockade. If cells lack the specific
therapeutic target or develop a means of bypassing its role in promoting tumour
growth, the therapy ceases to work. Similarly, if delivery of the drug to the tumour
is impaired, inadequate drug levels may allow cells to survive. While radionuclide
therapy also relies on target expression, it is possible to measure the expression of
any given target in individual lesions serially over time and on a whole-body scale.
Thus, the task of selecting patients for radionuclide therapy and predicting which
lesions will respond, and those that are unlikely to, is significantly easier than it is
for targeted therapies where treatment selection is typically made on the basis of a
tiny piece of biopsy material, which is assumed to be representative of all sites of
disease. Furthermore, unlike drugs that require each cell to express the target, the
particle range of many therapeutic isotopes means that a cell with high uptake can
lethally irradiate nearby cancer cells that might themselves either lack the target or
take up insufficient of the agent to have a direct toxic effect. The recognition of
microscopic tissue heterogeneity within tumours provides a strong rational basis for
Table 21.4 Other tracers being evaluated at the Peter MacCallum Cancer Centre
Agent Abbreviation Process Clinical use
18F-Fluoronicotinamide MEL-50 Melanin Melanoma
64Cu-SAT-octreotate CuSARTATE SSTR NET
79Zr-trastuzumab Zr-CEPTIN HER-2 receptor Breast cancer
124I-metomidate I-124 rituxan Cortisol synthesis Adrenocortical cancer
SSTR somatostatin receptor, NET neuroendocrine tumour
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radionuclide therapy with crossfire effect overcoming spatial heterogeneity of
target expression, at least at the microscopic scale.
While the old war horses, I-131 and Y-90, remain important therapeutic radio-
nuclides, the renaissance of radionuclide therapy has been driven y the development
of Lu-177. The physical characteristics of this isotope make it highly attractive for
therapy. Although it has sufficient gamma emissions to allow reasonably highly-
quality post-therapy imaging, they are not so abundant to pose a major external
radiation hazard allowing treatment to usually be performed on an outpatient basis.
The decay rate delivers radiation over several weeks but the beta-particle range of
only 1–2 mm means that relatively little radiation is delivered to normal cells close
to tumour deposits. This is especially beneficial for treating patients with rather
heavy infiltration of the liver or bone marrow. Recent studies have also indicated
the potential of alpha-particle-emitting radionuclides such as Ra-223 [26], which
deliver radiation over only a few cell diameters.
Lu-177 DOTA-octreotate (LuTate) has revolutionised our treatment of NET.
Building on the pioneering work of the Erasmus Medical Center in Rotterdam,
Holland, we added radiosensitising chemotherapy to the therapeutic regimen [27]
and have achieved excellent progression-free and overall survival rates even in
patients who would be considered to have a poor prognosis based on the presence of
high FDG avidity [28]. The key to achieving such outcomes has, however, been
ensuring that there are no lesions with FDG uptake that lack sufficient somatostatin
receptor to deliver effective radiation [29]. Again, this reflects a cogent example of
the theranostic paradigm wherein personalised selection of treatment can be based
on “if you can see it, you can treat it”.
Another example of this approach has been the development of PSMA-binding
ligands that are labelled with either I-131 [30] or Lu-177 [31]. Although prelimi-
nary, the results look impressive in patients with advanced castrate-resistant pros-
tate cancer. As is often the case, the patients referred for such trials have often been
heavily pretreated with several lines of therapy and have large burdens of disease.
Our own “compassionate use” eligibility criteria similarly allowed treatment of
patients who would almost certainly be ineligible for most industry-sponsored trials
of novel chemotherapy or targeted agents.
Herein lies a major future issue for nuclear medicine. We see patients who are
often at death’s door; we usually referred them only when another oncologist has
effectively abandoned the patient’s care for lack of any other options and has little
incentive to ever see the patient again. We see the wonderful benefit that some,
indeed many, patients derive, but this is usually reported in case series that lack
rigorous prospective design, defined eligibility criteria or standardised response and
toxicity assessment. Accordingly, the medical community often view these trials as
being flawed at best and anecdotal at worst.
If we are going to have radionuclide therapy assume the respectability it
deserves as a cancer therapy, we need to adopt the trial methodology used by
drug companies and stick to clearly defined protocols. There are certainly encour-
aging moves in this direction with both industry-funded and cooperative group
trials being developed that integrate radionuclide therapy.
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21.5 Long-Lived PET Isotopes with Therapeutic Pairs
Provide the Vehicle for Improved Radionuclide
Therapy Selection and Planning
One of the major impediments to establishing a scientific foundation for radionu-
clide therapy has been the inability to both predict and verify the radiation dose
delivered to both tumour and normal tissues. Although planar imaging has been
able to provide estimates of radiation to normal organs, the development of three-
dimensional and quantitative capability of hybrid scanners have made it possible to
use PET/CT to perform predictive dosimetry while quantitative SPECT/CT is being
refined to allow dose verification.
My group has established methods for quantitative Lu-177 SPECT/CT [32]. This
has taught us that while uptake of GaTate on pretreatment PET/CT provides a
reasonable estimate of what radiation will be delivered to tumour deposits, it is
clear that clearance kinetics of normal organs, particularly the kidneys, varies
considerably between patients and cannot be adequately modelled using short-
lived tracers. This is where longer-lived PET radionuclides will play an important
role. For predictive dosimetry of I-131 agents, I-124 provides the ideal combination
of a reasonably comparable physical half-life and excellent imaging characteristics.
Cu-64 provides an interesting opportunity for predictive dosimetry of its therapeu-
tic pair Cu-67 but could also be used as a PET surrogate for Lu-177 [33]. Zr-89 and
Y-90 provide another interesting combination with respect to
radioimmunotherapies.
In the future, the theranostic paradigm will hopefully change from a rather
empiric approach of “see it, guess an administered activity and treat it in hope” to
one that could be characterised as “see it, measure it, predict and verify therapeutic
radiation delivery within tolerance of normal tissues”. As is often the case, the past
can teach us useful lessons.
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